These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Influence of the conditions in pharmacophore generation, scoring, and 3D database search for chemical feature-based pharmacophore models: one application study of ETA- and ETB-selective antagonists. Cucarull-González JR; Laggner C; Langer T J Chem Inf Model; 2006; 46(3):1439-55. PubMed ID: 16711764 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacophore model of integrin alphavbeta3 antagonists]. Cheng GY; Ni GH; Jiang FC Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055 [TBL] [Abstract][Full Text] [Related]
10. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. López-Rodríguez ML; Benhamú B; de la Fuente T; Sanz A; Pardo L; Campillo M J Med Chem; 2005 Jun; 48(13):4216-9. PubMed ID: 15974573 [TBL] [Abstract][Full Text] [Related]
11. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Aulakh GK; Sodhi RK; Singh M Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338 [TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. Barreca ML; Gitto R; Quartarone S; De Luca L; De Sarro G; Chimirri A J Chem Inf Comput Sci; 2003; 43(2):651-5. PubMed ID: 12653534 [TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. Webb ML; Patel PS; Rose PM; Liu EC; Stein PD; Barrish J; Lach DA; Stouch T; Fisher SM; Hadjilambris O; Lee H; Skwish S; Dickinson KE; Krystek SR Biochemistry; 1996 Feb; 35(8):2548-56. PubMed ID: 8611558 [TBL] [Abstract][Full Text] [Related]
14. Computer--based drug design, synthesis and biological evaluation of new pyrimidinone derivatives linked to arylpiperazine and 2'-carbethoxy-biphenylylmethyl moeities as alpha1-adrenoceptor antagonists and angiotensin II AT1 receptor antagonists. Ismail MA; Abou El Ella DA; Abouzid KA; Al-Ansary GH Pharmazie; 2010 Nov; 65(11):794-800. PubMed ID: 21155384 [TBL] [Abstract][Full Text] [Related]
15. Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Chan MF; Okun I; Stavros FL; Hwang E; Wolff ME; Balaji VN Biochem Biophys Res Commun; 1994 May; 201(1):228-34. PubMed ID: 8198578 [TBL] [Abstract][Full Text] [Related]
16. QSAR studies on 3-(4-biphenylmethyl) 4, 5-dihydro-4-oxo-3H-imidazo [4, 5-c] Pyridine derivatives as angiotensin II (AT1) receptor antagonist. Sharma MC Interdiscip Sci; 2015 Jun; 7(2):113-28. PubMed ID: 26215494 [TBL] [Abstract][Full Text] [Related]
17. First pharmacophoric hypothesis for T-type calcium channel blockers. Doddareddy MR; Jung HK; Lee JY; Lee YS; Cho YS; Koh HY; Pae AN Bioorg Med Chem; 2004 Apr; 12(7):1605-11. PubMed ID: 15028253 [TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists. Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912 [TBL] [Abstract][Full Text] [Related]
20. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives. Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]